Navion Insights | February 2025
GLP-1s, Weight Loss & Rising Drug Spend: How Employers Can Adapt
By Beckie Fenrick, Pharm D , Emily Crisano PharmD, RPh and Jason Peterson , RPh
The demand for GLP-1 medications continues to rise, driven by new FDA approvals and increased consumer interest in weight loss treatments. As utilization grows, employers and health plans face mounting costs and complex coverage decisions. With prices soaring and demand showing no signs of slowing, the question isn’t just how to manage GLP-1s—but whether the current approach to coverage is sustainable.
The Power of Independent PBM Rebate Reconciliation
Many organizations assume their PBM rebate reconciliations are accurate—but without an independent review, substantial savings may be left unclaimed. Let's explore how a data-driven, independent reconciliation ensures full compliance, maximized savings and financial transparency.